Background The objective of this article is to summarize the published literature concerning
the pharmacokinetics and pharmacodynamics of oral anticoagulant drugs that are currently …

pharmacokinetics and pharmacodynamics of oral anticoagulant drugs that are currently
available for clinical use and other aspects related to their management. Methods: We …

Vitamin K antagonists were the only class of oral anticoagulants available to clinicians for
decades. However, with the US Food and Drug Administration approval of new oral …

Oral anticoagulation has been limited to vitamin K antagonists (VKAs) for over 60 years.
VKAs are effective and recommended for the prevention of venous and arterial …

While parenteral anticoagulants such as unfractionated and low molecular weight heparins
and the oral vitamin K antagonists are effective for the prevention and treatment of …

Although their first application in clinical practice occurred in the 1940s, vitamin K
antagonists remain the only form of oral anticoagulant medication approved for long-term …

New oral anticoagulants (OACs) that directly inhibit Factor Xa (FXa) or thrombin have been
developed for the long-term prevention of thromboembolic disorders. These novel agents …

Anticoagulation for the prevention of stroke is an important aspect of the management of
atrial fibrillation. Novel anticoagulants including oral factor Xa inhibitors rivaroxaban and …

Anticoagulation for the long-term treatment and prevention of thrombo-embolic diseases as
well as for stroke prevention in atrial fibrillation (AF) has been accomplished by vitamin K …

The risk of bleeding in the setting of anticoagulant therapy continues to be re-evaluated
following the introduction of a new generation of direct oral anticoagulants (DOACs) …